Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oragenics Inc. Common Stock (NY:OGEN)

0.2068 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oragenics Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Oragenics (OGEN) Stock Is Getting Hammered
Oragenics shares are trading lower by 47% during Wednesday's session. The company announced a $4.45 million public offering. 
Via Benzinga
US Stocks Mixed; Trade Gap Widens In July
Via Benzinga
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
Via Investor Brand Network
EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury
Oragenics completes the formulation and filling of its nasal spray drug, ONP-002, for concussion treatment, aiming to launch a Phase 2a trial. 
Via Benzinga
OGEN Stock Earnings: Oragenics Reported Results for Q2 2024
Oragenics just reported results for the second quarter of 2024. 
Via InvestorPlace
OGEN Stock Earnings: Oragenics Reported Results for Q4 2023
Oragenics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
Via Investor Brand Network
Exposures Product Safety
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Why Oragenics (OGEN) Shares Are Falling
Oragenics shares are trading lower by 21% during Tuesday's session. The company announced pricing of its public offering. 
Via Benzinga
OGEN Stock Earnings: Oragenics Reported Results for Q1 2024
Oragenics just reported results for the first quarter of 2024. 
Via InvestorPlace
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
Oragenics announced its lead candidate, ONP-002, for treating concussion, which shows no cardiotoxicity in studies. Designed for nasal delivery to the brain, ONP-002 aims to address the significant... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results
Via Benzinga
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Gold Down Over 1%; Williams-Sonoma Posts Strong Earnings
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Closing of Public Offering
From Oragenics, Inc.
Via Business Wire
S&P 500 Edges Lower; ADT Posts Upbeat Earnings
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.